Should Pharma Release IP For COVID-19 Research? Novartis Exec Weighs In

As World Health Assembly prepares resolution for voluntary pooling and licensing, Novartis global head of IP Corey Salsberg discusses how intellectual property is advancing development of therapeutics and vaccines and the benefits of voluntary rather than compulsory licensing; 

Patent Health Care Pharmaceuticals Innovation concept.
Intellectual property is central to COVID-19 innovation and collaboration, Novartis exec says

The World Health Organization, nonprofit groups, and others have called on the biopharmaceutical industry to make its intellectual property available for the development of products to halt the COVID-19 pandemic. What is industry's view on this push? Biopharma attorneys gave their perspectives in a recent webinar.

The Federal Circuit Bar Association hosted the 7 May event, which consisted of a Q&A with IP counsel. They were...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet